ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 2.03 USD 3.57% Market Closed
Market Cap: 196.3m USD
Have any thoughts about
ADC Therapeutics SA?
Write Note

ADC Therapeutics SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ADC Therapeutics SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
ADC Therapeutics SA
NYSE:ADCT
Cash from Financing Activities
$73.9m
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Cash from Financing Activities
CHf40.1m
CAGR 3-Years
51%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Cash from Financing Activities
$354.1m
CAGR 3-Years
-19%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Cash from Financing Activities
-CHf1.2m
CAGR 3-Years
N/A
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Cash from Financing Activities
-CHf53.4m
CAGR 3-Years
N/A
CAGR 5-Years
-67%
CAGR 10-Years
N/A
Kuros Biosciences AG
SIX:KURN
Cash from Financing Activities
CHf666k
CAGR 3-Years
-66%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
No Stocks Found

ADC Therapeutics SA
Glance View

Market Cap
196.3m USD
Industry
Biotechnology

ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

ADCT Intrinsic Value
4.99 USD
Undervaluation 59%
Intrinsic Value
Price

See Also

What is ADC Therapeutics SA's Cash from Financing Activities?
Cash from Financing Activities
73.9m USD

Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Cash from Financing Activities amounts to 73.9m USD.

What is ADC Therapeutics SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-47%

The average annual Cash from Financing Activities growth rates for ADC Therapeutics SA have been -47% over the past three years .

Back to Top